GUERBET Vendor's profile
FDA Approves Dotarem®, first macrocyclic and ionic gadolinium-based contrast agent in USA
Donnerstag, 21. März 2013
Guerbet announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pe...
FDA Approves Lipiodol® Injection for Imaging of Tumors in Adults with Known Hepatocellular Carcinoma
Donnerstag, 10. April 2014
FDA Approves Lipiodol® (Ethiodized Oil) Injection for Imaging of Tumors in Adults with Known Hepatocellular Carcinoma (HCC) Princeton (NJ), Guerbet, a pioneer in the field of contrast agents for medical imaging announced that Lipiodol® was approved by the US Food and Drug Administration purs...
Dotarem® (gadoterate meglumine) Injection Now Offered Via Novation
Dienstag, 12. November 2013
Villepinte, 12 November 2013 Guerbet LLC (USA) announced that Novation, the leading healthcare supply chain expertise, analytics and contracting company in the US, has awarded a new agreement for Dotarem® (gadoterate meglumine) Injection. Dotarem® is a gadolinium-based contrast age...
To feature here : Get in touch
Patient-Specific Radiation Dose Estimation in Breast Cancer Screening
Increasing interventional radiology capacity while reducing patient radiation
A healthy dose of radiation monitoring
The first fully digital C-arm
Ensuring performance of x-Ray equipment: a holistic approach